Shares closed at $1.51 on Friday as trading volume reached 10.1 million, above the 50-day average of 9.7 million.
The gain ended a three-day losing streak during a broadly positive session in which the S&P 500 rose 0.84% and the Dow Jones Industrial Average added 0.02%.
Despite the rebound, Ocugen remains 44.59% below its 52-week high of $2.73 reached on 17 March.
With short interest surging, what critical risk are bullish analysts overlooking in Ocugen's future?
Is Ocugen's gene therapy for blindness a revolutionary cure or just speculative biotech hype?